Form 8-K PLIANT THERAPEUTICS, For: Jul 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Form 8-K PLIANT THERAPEUTICS, For: Jul 10
July 11, 2022 10:22 AM EDT
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $54.00 price target on Pliant Therapeutics (NASDAQ: PLRX)
The analyst comments "We highlight several tidbits emerging from the company's conference call this morning with more details from the ph.II '809 IPF study. In... More
July 11, 2022 9:47 AM EDT
Pliant Therapeutics Inc. (NASDAQ: PLRX) Halted Again on Volatility, Up 141%
...
More
July 11, 2022 9:32 AM EDT
Pliant Therapeutics Inc. (NASDAQ: PLRX) Halted on Volatility, Up 103%
...
More
July 11, 2022 9:01 AM EDT
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $45.00 price target on Pliant Therapeutics (NASDAQ: PLRX).
The analyst comments "Last night, we spoke with Pliant management following yesterday's eagerly awaited release of the top-line results of its Phase 2a INTEGRIS-IPF study (NCT04396756) of lead drug PLN-74809 administered over 12 weeks in 90 patients with idiopathic pulmonary fibrosis (IPF). Importantly, across the three active dose arms (40, 80 and 160 mg) plus placebo, 80% of enrolled patients were on stable doses of standard-of-care (SoC), equally distributed between nintedanib and pirfenidone. As we expected, and consistent with prior... More
